Holen Sie sich die Stockscreener-App
126.98
0.13%
0.16
Handel nachbörslich:
126.98
Schlusskurs vom Vortag:
$126.82
Offen:
$127.46
24-Stunden-Volumen:
1.34M
Relative Volume:
0.87
Marktkapitalisierung:
$268.24B
Einnahmen:
$53.40B
Nettoeinkommen (Verlust:
$13.68B
KGV:
18.34
EPS:
6.9231
Netto-Cashflow:
$16.89B
1W Leistung:
+2.23%
1M Leistung:
+8.69%
6M Leistung:
+16.12%
1J Leistung:
+7.83%
1-Tages-Spanne:
$126.86
$128.03
1-Wochen-Bereich:
$123.79
$128.03
52-Wochen-Spanne:
$96.06
$128.03
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com
NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com
Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar
Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView
Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com
5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com
NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Why Value Investing Has Worked Better Outside the US - Morningstar
Which Industries are shaken when Trump's tariff stick swings towards the EU? - 富途牛牛
Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.50%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):